Literature DB >> 32061922

TSH/IGF1 receptor crosstalk: Mechanism and clinical implications.

Christine C Krieger1, Susanne Neumann1, Marvin C Gershengorn2.   

Abstract

Increasing evidence of interdependence between G protein-coupled receptors and receptor tyrosine kinase signaling pathways has prompted reevaluation of crosstalk between these receptors in disease and therapy. Investigations into thyroid-stimulating hormone (TSH) and insulin-like growth factor 1 (IGF1) receptor crosstalk, and its application to the clinic have in particular shown recent progress. In this review, we summarize current insights into the mechanism of TSH/IGF1 receptor crosstalk. We discuss evidence that crosstalk is one of the underlying causes of TSHR-based disease and the feasibility of using combinations of TSH receptor and IGF1 receptor antagonists to increase the therapeutic index for the treatment of Graves' hyperthyroidism and Graves' ophthalmopathy.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Graves' ophthalmopathy fibroblasts; Insulin-like growth factor 1 receptor; Receptor crosstalk; TSH receptor stimulating antibodies; Thyroid-stimulating hormone receptor

Mesh:

Substances:

Year:  2020        PMID: 32061922      PMCID: PMC7187798          DOI: 10.1016/j.pharmthera.2020.107502

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  39 in total

1.  Thyrotropin and Insulin-Like Growth Factor 1 Receptor Crosstalk Upregulates Sodium-Iodide Symporter Expression in Primary Cultures of Human Thyrocytes.

Authors:  Sarah J Morgan; Susanne Neumann; Bernice Marcus-Samuels; Marvin C Gershengorn
Journal:  Thyroid       Date:  2016-10-18       Impact factor: 6.568

2.  TSHR/IGF-1R Cross-Talk, Not IGF-1R Stimulating Antibodies, Mediates Graves' Ophthalmopathy Pathogenesis.

Authors:  Christine C Krieger; Susanne Neumann; Bernice Marcus-Samuels; Marvin C Gershengorn
Journal:  Thyroid       Date:  2017-03-27       Impact factor: 6.568

Review 3.  IGF1 receptor and thyroid-associated ophthalmopathy.

Authors:  Michelle Mohyi; Terry J Smith
Journal:  J Mol Endocrinol       Date:  2017-12-22       Impact factor: 5.098

4.  A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody.

Authors:  Seema Kumar; Seethalakshmi Iyer; Hilary Bauer; Michael Coenen; Rebecca S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

Review 5.  Immunotherapies for thyroid eye disease.

Authors:  George J Kahaly
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2019-10       Impact factor: 3.243

6.  Human monoclonal thyroid stimulating autoantibody.

Authors:  J Sanders; M Evans; L D K E Premawardhana; H Depraetere; J Jeffreys; T Richards; J Furmaniak; B Rees Smith
Journal:  Lancet       Date:  2003-07-12       Impact factor: 79.321

7.  TSH/IGF-1 Receptor Cross-Talk Rapidly Activates Extracellular Signal-Regulated Kinases in Multiple Cell Types.

Authors:  Christine C Krieger; Joseph D Perry; Sarah J Morgan; George J Kahaly; Marvin C Gershengorn
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

Review 8.  Therapeutic Potential of Targeting ß-Arrestin.

Authors:  Richard A Bond; Emilio Y Lucero Garcia-Rojas; Akhil Hegde; Julia K L Walker
Journal:  Front Pharmacol       Date:  2019-03-06       Impact factor: 5.810

9.  Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study.

Authors:  Simon H S Pearce; Colin Dayan; David C Wraith; Kevin Barrell; Natalie Olive; Lotta Jansson; Terrie Walker-Smith; Christina Carnegie; Keith F Martin; Kristien Boelaert; Jackie Gilbert; Claire E Higham; Ilaria Muller; Robert D Murray; Petros Perros; Salman Razvi; Bijay Vaidya; Florian Wernig; George J Kahaly
Journal:  Thyroid       Date:  2019-06-13       Impact factor: 6.568

Review 10.  Therapeutic Targeting of the IGF Axis.

Authors:  Eliot Osher; Valentine M Macaulay
Journal:  Cells       Date:  2019-08-14       Impact factor: 6.600

View more
  12 in total

1.  Targeting TSH and IGF-1 Receptors to Treat Thyroid Eye Disease.

Authors:  Susanne Neumann; Christine C Krieger; Marvin C Gershengorn
Journal:  Eur Thyroid J       Date:  2020-11-02

2.  Modulating TSH Receptor Signaling for Therapeutic Benefit.

Authors:  Gerd Krause; Anja Eckstein; Ralf Schülein
Journal:  Eur Thyroid J       Date:  2020-11-23

3.  Editorial: Mechanisms and Novel Therapies in Graves' Orbitopathy: Current Update.

Authors:  Huifang Zhou; Ilaria Muller; Kelvin Kam-Lung Chong; Marian Ludgate; Sijie Fang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-29       Impact factor: 6.055

Review 4.  Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-17       Impact factor: 5.555

Review 5.  Mechanisms That Underly T Cell Immunity in Graves' Orbitopathy.

Authors:  Sijie Fang; Yi Lu; Yazhuo Huang; Huifang Zhou; Xianqun Fan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-01       Impact factor: 5.555

6.  Obese patients with higher TSH levels had an obvious metabolic improvement after bariatric surgery.

Authors:  Nannan Bian; Xiaomeng Sun; Biao Zhou; Lin Zhang; Qiu Wang; Yu An; Xiaohui Li; Yinhui Li; Jia Liu; Hua Meng; Guang Wang
Journal:  Endocr Connect       Date:  2021-10-13       Impact factor: 3.335

Review 7.  Thyroid eye disease: From pathogenesis to targeted therapies.

Authors:  Jin Sook Yoon; Don O Kikkawa
Journal:  Taiwan J Ophthalmol       Date:  2022-01-21

8.  MiR-143 Targets IGF-1R to Suppress Autoimmunity in Thyroid-Associated Ophthalmopathy.

Authors:  Wei Tang; Qian Lv; Xiao Huang; Yuzhen Li; JunJie Zou; Jiaoyang Zheng; Liangliang Sun; Yi Bao; Haiyan Chen; Tuo Li; Bei Zhang; Song Xue; Yan Song; Xingxing Zhang; Xiangfang Chen; Jiping Cai; Yongquan Shi
Journal:  J Inflamm Res       Date:  2022-03-01

9.  2022 European Thyroid Association Guideline for the management of pediatric Graves' disease.

Authors:  Christiaan F Mooij; Timothy D Cheetham; Frederik A Verburg; Anja Eckstein; Simon H Pearce; Juliane Léger; A S Paul van Trotsenburg
Journal:  Eur Thyroid J       Date:  2022-01-01

10.  TSH lowering effects of metformin: a possible mechanism of action.

Authors:  R Cannarella; R A Condorelli; F Barbagallo; A Aversa; A E Calogero; S La Vignera
Journal:  J Endocrinol Invest       Date:  2020-10-14       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.